his general pharmacodynamic model consisting of two sub-functions that divide the pharmacodynamic cascade from drug concentration to cell effect/response into two successive steps:
This paper was inspired by recent pharmacodynamic models of Torda et al 1 . In this paper, we first discuss the strengths and weaknesses of the Torda models, then we review the Waud general pharmacodynamic model, and finally, we propose a new population-effect-function for the Waud model that explains why the recovery of neuromuscular block is sigmoid 2 . The hypothesis is examined using patient material.
Torda Models
Torda et al have proposed Normal and LogNormal pharmacodynamic models for antagonists, such as competitive neuromuscular blocking agents (NMBA) 2 .
In this equation, fractional muscle effect E f is the cumulative Normal function of drug concentration [D] or logarithmic drug concentration log [D] , y is the integration parameter of [D] or log [D] , Y m is the mean blocking concentration of the antagonist and σ the respective standard deviation. The models suggest that the distribution of the sensitivities of individual muscle fibres to respond is either Normal or LogNormal with respect to NMBA concentration. The goodness-of-fits of the Torda models to empirical data are indistinguishable from the widely used Hill equation model, which is not surprising since it is difficult to obtain data with sufficient precision from early and late recovery to demonstrate the superiority of either one of the models 1 5 . The Hill equation model also defines non-physiological sigmoid responses for individual muscle fibres, the response/effect of which is actually always all-ornone, contraction or no contraction. The strength of the Torda models is that they define population responses that can be sigmoid even if the responses of individual fibres are all-or-none, i.e., follow a stepfunction. Torda models fail to take drug-receptor binding into account and so should also be regarded as computational.
General Pharmacodynamic Model
Neither the Torda models nor the Hill equation model follow the general pharmacodynamic model presented by Waud in 1968
where the observed fractional effect E f is a function F of drug concentration [D] and time t 2 . The function F may consist of several sub-functions. Waud has suggested that the pharmacodynamic cascade from drug concentration to cell effect/ response may be divided into two successive steps: 1) the binding of agonist drug molecules to the postsynaptic receptors and the subsequent receptor activation (agonist-induced conformational change of closed-channel state receptors to open channel-state receptors), and 2) the cell response induced by receptor activation 2 . Fractional receptor activation Y ac is the first step in the pharmacodynamic cascade and it may be determined by the drug concentration [D] and time t according to a function g 2 ,
Function g may be substituted by current kinetic models of nicotinic acetylcholine receptor conformational transitions 6 . According to Waud, the problem of determining the relation between drug concentration and cell response/effect reduces to the determination of the relation between fractional receptor activation and the cell response, which is the second step in the pharmacodynamic cascade 2 . In short, fractional cell effect E f is a function f of Y ac and time t 2 ,
Combining the above formulas yields
where f is the external and g the internal sub-function of the general function F in the Waud general model 2 .
In this mathematical formula, concentration [D] is the only nondependent parameter. In other words, the cell effect/response E f depends on the level of receptor activation Y ac , which itself depends on the drug concentration [D], not vice versa (see Scheme 1) .
Waud has presented a widely accepted general pharmacodynamic formula but he has not specified the external/effect-function for muscle fibres 2 . We state that the effect-function f must be a step function from zero to one because the responses of muscle fibres are all-or-nothing-type. The problem in the pharmacodynamic modelling of neurally stimulated muscle responses reduces now to the determination of the distribution of individual step-effect-functions f with respect to the mean fractional receptor activation in end-plate populations.
Probability Distribution of Responding Muscle Fibres
The peak density of activated receptors, which is responsible for the peak end-plate depolarization, depends at least on the following factors: The quantity and time course of transmitter release, the distances of post-synaptic receptors from the sites of transmitter release in the neuromuscular junction (NMJ), the activity and concentration of acetylcholine-esterase in the NMJ, the number and density of post-synaptic receptors in the end-plate and the concentration and type of antagonist-drug in the NMJ and the availability of free receptors for the agonist to act on. The speed of recovery depends on the pharmacokinetics of the antagonist. The effects of these factors on the peak density of activated receptors vary between end plates at the same moment and even in a single end plate over time. The peak end-plate depolarization (provided that the end-plate potential does not reach the threshold level) is linearly dependent on the peak density of activated receptors since the conductance of postsynaptic ionic channels is linearly, not exponentially, dependent on the membrane potential 7, 8 , that is, the increase in the number of activated receptors needed for a depolarization unit is linearly dependent on the membrane potential. Because of this linear relationship, both the peak end-plate depolarization and the peak density of activated receptors must have approximately the same type of variation in a muscle fibre population.
After neural stimulation, the probability of a muscle fibre responding depends on its threshold depolarization 9 (the difference between the resting and the threshold potentials) and the peak end-plate depolarization. The distribution of the sensitivities of muscle fibres to respond is a weighted average of the distributions of the threshold depolarizations and peak end-plate depolarizations, which themselves are weighted averages of the distributions of the effects of several factors listed above. We suggest here that this distribution is Gaussian or Normal. The observed fractional muscle response reflects the probability of muscle fibres to respond and, thus, follows the cumulative Normal function.
The Cumulative Normal Population-Effect-Function
Our hypothesis is that the probability/proportion of muscle fibres in a muscle fibre population to respond is cumulatively Normally distributed with respect to the mean fractional receptor activation Yac. We substitute the external/effect function f of the Waud general pharmacodynamic model (Equation 5) with the cumulative Normal function. Fractional muscle effect E f is a function of mean fractional receptor activation Yac, the integration parameter of which is y. Y m represents the level of mean fractional receptor activation that is able to produce half maximal population-effect and σ is the respective standard deviation.
MATERIAL AND METHODS
To test the hypothesis, we recorded electrically evoked electromyographical (EEMG) responses during clinical recovery of neuromuscular block (NMB) in stable anaesthetic conditions in eight informed consenting patients (ASA I) as approved by the local Ethics Committee. General anaesthesia was induced using glycopyrrolate 0.2 mg, fentanyl 2 µg/kg and thiopentone 4 to 5 mg/kg. Endotracheal intubation was performed without the aid of NMB drugs at 1.5 to 2 MAC isoflurane (ISO) anaesthesia. Anaesthesia was maintained with an ISO-nitrous oxide (N 2 O)oxygen mixture and incremental doses (1 µg/kg) of fentanyl. The NMT-module of the Datex-Ohmeda AS/3 Anesthesia Monitor (Datex-Ohmeda Division, Instrumentarium Corporation, Helsinki, Finland) was used to stimulate the ulnar nerve at the wrist (200 µs monophasic supramaximal pulses, train-offour, 2 Hz, every 60 s) and to record the integrated area of the EEMG signal. The active electrode was placed on the first dorsal interosseous muscle and the reference electrode on the index finger. EEMG responses, end-tidal carbon dioxide (ETCO 2 ), nitrous oxide (ETN 2 O), and isoflurane (ETISO), temperatures of the skin above the measured muscle and the oesophageus were recorded every 60 s and noninvasive blood pressure every five minutes using the Datex-Ohmeda Collect program running on a PC. After anaesthesia had stabilized (variation in ETCO 2 = ±0.1%, ETN 2 O= ±3%, ETISO= ±0.1%) and recorded signals had been constant for five minutes (change of skin temperature over the muscle <±0.1°C, and of EMG baseline <±1%), full neuromuscular block was induced by mivacurium 0.1 mg/kg IV in five patients and with vecuronium 0.6 mg/kg IV in three patients. All other recorded parameters were kept constant during spontaneous recovery from NMB, which was monitored until the original baseline level was reached (evoked responses within ±1% of baseline for five minutes).
Analysis of Normality
The recorded recoveries started from E1 <0.02 (the first EMG response to the train of four stimulation) and continued until E1 reached >0.98. To test the cumulative Normality of the recorded recovery curves, we divided the duration of each recorded recovery into 20 equal time intervals. Individual recoveries and the mean recovery of all recordings over time-periods are depicted in Figure 1 . Numerically derived recovery responses give the frequency values of new responding fibres in each time period. These frequency distributions were tested for Normality using the Kolmogorov-Smirnov test (SigmaStat 2.0, Jandel Scientific Corporation, San Rafael, CA, U.S.A). A P value of 0.05 was used in the test. The P value determines the probability of being incorrect in assuming that the data is not normally distributed. If the computed P is greater than 0.05, the test passes. The normal plot was constructed using Normsinv-function (Excel, Microsoft Corporation, U.S.A.) to get the standard deviations of the averaged recovery values on the linear timeunit scale. The Normality of the averaged recovery curve was judged visually by the linearity of its normal plot. The same curve is obtained by using a probability scale on the y axis. A Logit-scale was also used for comparison ( Figure 1 ).
RESULTS
Four out of five mivacurium and all the three vecuronium frequency data passed the Kolmogorov-Smirnov normality test at P>0.05 as did the averaged frequency data of the separate mivacurium and vecuronium groups. The total averaged frequency 373 NORMAL DISTRIBUTION OF FIRING SENSITIVITY Anaesthesia and Intensive Care, Vol. 29, No. 4, August 2001 (7) data (Figure 1 ) passed the normality test at P=0.085, K-S Distance=0.181. Skewness and kurtosis of the total averaged data were 0.761 and 0.427, respectively. The normal plot of the averaged recovery data was visually reasonably linear to match a muscle fibre population with a normal distribution (Figure 1) . The slight bending of the curve is interpreted to reflect pharmacokinetics of the antagonist drug in the neuromuscular junctions.
DISCUSSION
All study designs possess confounding factors that may result in noise and systematic errors in the recordings. Curve fitting alone can not positively confirm the hypothesis that the distribution of muscle fibre excitability with respect to the fractional receptor activation is definitely cumulatively normal.
Our initial goal was to determine the population external/effect-function for the Waud general pharmacodynamic model that would define the distribution of muscle fibre excitability with respect to the mean fractional receptor activation, i.e., the cumulative neuromuscular recovery pattern. Several distributions are used in medical statistical literature. The Binomial distribution used for discrete data and proportions cannot explain the sigmoid shape of muscle fibre excitability because the probability of fibre excitation cannot be determined by a constant proportion during the neuromuscular recovery phase. Neither is the Poisson distribution, used for rare independent random phenomena, rational for the circumstance because muscle fibre excitations do not occur in time at fixed rate on average during the neuromuscular recovery phase. The normal distribution and its variations are used to describe continuous variables and are the only distributions that can be applied for this purpose.
The established use of Log-Probit or Log-Probability-fit paper in muscle relaxation studies already accepts the normality of muscle fibre responsiveness over logarithmic drug concentrations/ doses [10] [11] [12] . This method of neuromuscular data analysis corresponds to the Torda LogNormal model described above (Equation 1) 1 .
During clinical recovery of NMB, as antagonist concentration decreases, more and more muscle fibres become responsive to nerve stimulation over time forming a cumulative recovery pattern, which is more or less sigmoid. The main problem of our study design was its time dependency. If the mean peak end-plate depolarization/mean fractional receptor activation Y ac (the variable of the external function of the Waud general pharmacodynamic model) increases linearly over time, the shape of the curve of clinical recovery from NMB would follow the cumulative Normal function. In clinical circumstances, the neuromuscular recovery curve is more or less skewed by pharmacokinetic factors.
In our study, seven of the eight sets of frequency data collected, the averaged frequency data for mivacurium and vecuronium groups and the total averaged frequency data, all passed the normality test, suggesting that the hypothesis was correct and that the general shape of neuromuscular recoveries is not drug-dependent.
As illustrated in Figure 2 , the cumulative Normal population-effect-function defines sigmoid relationships between the mean fractional receptor activation Y ac, fractional muscle effect E f and logarithmic antagonist concentration log[D]. In Figure 2 , Paton's and Waud's "threshold" fractions of blocked receptors determining the minimal and maximal measurable muscle responses are approximated to correspond to the mean fractional receptor activations Y ac of 0.10 and 0.25, respectively 13 . In addition, the equilibrium law of mass action Y ac =[D]/(K D +[D]) is used for simplicity as the internal function g of the Waud general pharmacodynamic model (Equation 5) 14 . If the junctional antagonist concentration decrease is actually logarithmic, the same sigmoid relationships would exist between the mean fractional receptor activation Y ac , fractional muscle effect E f and time t.
A good fit of the model with empirical data is not enough to prove the model. At least as important is that the model follows logically the available mechanistic pharmaco-physiological knowledge without leaving any "black boxes" along the functional cascade. The cumulative Normal population-effectfunction passes both objectives. In conclusion, it is currently the only external/effect-function applied to the Waud general pharmacodynamic model that explains logically why the sigmoid muscle effect, from minimal to maximal, is seen in such a narrow range of antagonist concentrations 15, 16 and receptor occupancies 9, 13, 17 .
